what are beta-lacta mases
Reading File
Searching the Web
beta-lactamases classification mechanism of action 2025
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Now I have comprehensive textbook material. Let me compile a thorough answer.
Beta-Lactamases
Beta-lactamases are bacterial enzymes that confer resistance to beta-lactam antibiotics by hydrolyzing the amide bond of the beta-lactam ring, permanently inactivating the drug before it can reach its target (penicillin-binding proteins, or PBPs). They are the single most important mechanism of resistance to beta-lactam antibiotics in gram-negative bacteria.
Mechanism of Action
Beta-lactam antibiotics normally work by mimicking the D-Ala-D-Ala terminus of peptidoglycan precursors and irreversibly binding to PBPs, blocking cell wall synthesis. Beta-lactamases counteract this by attacking the beta-lactam ring:
- Serine beta-lactamases (Classes A, C, D): Use an active-site serine residue in a two-step reaction - acylation (covalent attachment of the antibiotic to the serine) followed by deacylation (hydrolysis releases the inactivated antibiotic and regenerates the enzyme).
- Metallo-beta-lactamases (Class B): Use one or two zinc ions at the active site to coordinate a water molecule that directly hydrolyzes the ring - no covalent intermediate, which is why these are NOT inhibited by classical beta-lactamase inhibitors.
Classification (Ambler Molecular Classes)
From Henry's Clinical Diagnosis and Management by Laboratory Methods (Table 58.1):
| Ambler Class | Active Site | Category | Examples | Key Features |
|---|---|---|---|---|
| A | Serine | ESBLs | CTX-M, SHV, TEM | Resistant to penicillins, 1st-3rd gen cephalosporins, aztreonam; inhibited by clavulanic acid, tazobactam, sulbactam |
| A | Serine | Carbapenemases | KPC, IMI, SME | Hydrolyze carbapenems; inhibited by avibactam and boronic acid; found in K. pneumoniae, E. coli |
| B | Metallo (zinc) | Carbapenemases (MBLs) | NDM, VIM, IMP, GIM, SPM-1 | Strongest carbapenem hydrolyzers; NOT inhibited by standard inhibitors (including avibactam); inhibited by EDTA; do NOT inactivate aztreonam |
| C | Serine | AmpC | ACC, FOX, LAT, MOX | Resistant to cephamycins (cefoxitin) AND beta-lactamase inhibitors; susceptible to carbapenems unless co-resistance present; inducible by beta-lactams |
| D | Serine | OXA carbapenemases | OXA-48, OXA-23 | Weak carbapenem hydrolysis; inhibited by oxacillin/temocillin; NOT inhibited by EDTA or boronic acid |
Clinically Important Types
1. Extended-Spectrum Beta-Lactamases (ESBLs)
- Derived from TEM and SHV penicillinases by point mutations, or the CTX-M family (now most common globally)
- Hydrolyze penicillins, all cephalosporins, and aztreonam
- Inhibited by clavulanic acid, sulbactam, and tazobactam
- Produced mainly by Enterobacteriaceae (especially E. coli, K. pneumoniae)
- Treatment: carbapenems remain the gold standard
2. AmpC Beta-Lactamases
- Class C, typically chromosomally encoded and inducible
- Produced by "SPACE" organisms: Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter
- NOT inhibited by clavulanic acid, tazobactam, or sulbactam
- Resistant to cephamycins (cefoxitin)
3. Carbapenemases (KPC, NDM, VIM, IMP, OXA)
- Hydrolyze carbapenems - the last-resort beta-lactams
- KPC (Klebsiella Pneumoniae Carbapenemase): Class A, inhibited by avibactam; found in K. pneumoniae and other Enterobacteriaceae
- NDM (New Delhi Metallo-beta-lactamase): Class B MBL, resistant to virtually all beta-lactams; NOT inhibited by avibactam
- OXA-48: Class D, carbapenem-resistant K. pneumoniae; partially inhibited by avibactam
Beta-Lactamase Inhibitors
From Katzung's Basic and Clinical Pharmacology, 16th Ed.:
| Inhibitor | Class Covered | Combinations Used |
|---|---|---|
| Clavulanic acid | Class A | Amoxicillin-clavulanate, ticarcillin-clavulanate |
| Sulbactam | Class A | Ampicillin-sulbactam |
| Tazobactam | Class A | Piperacillin-tazobactam |
| Avibactam | Class A, C, some D (OXA-48) | Ceftazidime-avibactam, ceftolozane-avibactam |
| Vaborbactam | Class A, C | Meropenem-vaborbactam |
| Relebactam | Class A, C (similar to avibactam) | Imipenem-cilastatin-relebactam |
None of these inhibit Class B metallo-beta-lactamases. NDM-producing organisms are therefore extremely difficult to treat.
Genetic Transmission
Beta-lactamase genes can be:
- Chromosomal (intrinsic, often inducible - e.g., AmpC in Enterobacter)
- Plasmid-encoded (transferable by conjugation between organisms - e.g., TEM/SHV/CTX-M ESBLs, KPC, NDM)
The plasmid-mediated spread is what makes ESBLs and carbapenemases such major public health threats.
Summary: Beta-lactamases are the primary defense bacteria use against beta-lactam antibiotics. The clinical response has been to develop inhibitor combinations, but the emergence of metallo-beta-lactamases (NDM, VIM, IMP) that resist all current inhibitors represents an ongoing therapeutic crisis in infectious disease.
- Katzung's Basic and Clinical Pharmacology, 16th Edition, p. 1318-1337
- Henry's Clinical Diagnosis and Management by Laboratory Methods, Table 58.1 (Beta-Lactamase Classification)
is MOA of penicillin G and amoxicillin are same?
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Yes - same MOA, different spectrum and pharmacokinetics. Here is the full picture:
Penicillin G vs. Amoxicillin: Same MOA?
Short answer: Yes. Both are beta-lactam antibiotics and share an identical mechanism of action. They differ in their antibacterial spectrum, acid stability, route of administration, and oral bioavailability.
Shared Mechanism of Action
From Lippincott Illustrated Reviews: Pharmacology:
"Penicillins interfere with the last step of bacterial cell wall synthesis, which is the cross-linking of adjacent peptidoglycan strands by a process known as transpeptidation. Since penicillins structurally resemble the terminal portion of the peptidoglycan strand (D-Ala-D-Ala), they compete for and bind to enzymes called penicillin-binding proteins (PBPs), which catalyze transpeptidase and facilitate cross-linking."
This applies to all penicillins - including penicillin G and amoxicillin.
Step-by-step:
- The beta-lactam ring mimics the D-Ala-D-Ala terminus of the peptidoglycan precursor
- PBPs (which are transpeptidases, carboxypeptidases) bind the drug covalently
- Cross-linking of peptidoglycan strands is blocked
- The cell wall becomes structurally weak
- Osmotic lysis and bacterial cell death follow (bactericidal effect)
Where They Differ
| Feature | Penicillin G | Amoxicillin |
|---|---|---|
| Class | Natural penicillin | Aminopenicillin (semisynthetic) |
| MOA | Inhibit PBPs / block transpeptidation | Identical |
| Spectrum | Narrow - mainly gram-positive, spirochetes, some gram-negative (Neisseria) | Broader - gram-positive + gram-negative (H. influenzae, E. coli, Listeria, Enterococci) |
| Acid stability | Acid-labile (destroyed by gastric acid) | Acid-stable |
| Route | Parenteral (IV/IM) primarily; penicillin V used orally | Oral (well absorbed); also IV |
| Food effect | Absorption reduced by food | Food does NOT interfere |
| Oral bioavailability | Poor | Excellent - peaks 2-2.5x higher than ampicillin |
From Lippincott: The antibacterial spectrum is determined by the ability to cross the bacterial peptidoglycan cell wall and reach PBPs in the periplasmic space, which depends on size, charge, and hydrophobicity of the specific drug. Amoxicillin's amino group allows better penetration through outer membrane porins of gram-negative bacteria, explaining its broader spectrum.
Why Amoxicillin Has a Broader Spectrum
The key structural difference is the amino group (-NH₂) on the alpha carbon of amoxicillin's side chain. This:
- Makes it more hydrophilic
- Allows better penetration through gram-negative outer membrane porin channels
- Extends activity to organisms like H. influenzae, E. coli, Enterococcus faecalis, Listeria
Penicillin G lacks this and cannot efficiently penetrate gram-negative outer membranes.
Summary
| Penicillin G | Amoxicillin | |
|---|---|---|
| MOA | PBP inhibition, block cell wall transpeptidation | Same |
| Effect | Bactericidal | Same |
| Spectrum | Narrow (gram-positive) | Wider (gram-positive + some gram-negative) |
| Use | IV/IM - serious infections (syphilis, meningitis, endocarditis) | Oral - community infections (otitis, sinusitis, UTI, H. pylori) |
Both are hydrolyzed and inactivated by beta-lactamases, so neither has intrinsic activity against beta-lactamase-producing organisms unless combined with an inhibitor (e.g., amoxicillin-clavulanate).
- Lippincott Illustrated Reviews: Pharmacology, p. 942-943
- Goodman & Gilman's Pharmacological Basis of Therapeutics, p. 1170, 753
- Katzung's Basic and Clinical Pharmacology, 16th Ed.
This is a shared conversation. Sign in to Orris to start your own chat.